Surrozen 

$0.001300
12
-$0.00-65.79% Friday 17:08

Statistics

Day High
0.0015
Day Low
0.0015
52W High
0.0015
52W Low
0.0013
Volume
26,468
Avg. Volume
-
Mkt Cap
15,279.63
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-11.65
-6.92
-2.18
2.55
Expected EPS
-1.103867
Actual EPS
N/A

Financials

-6,960.77%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.48MRevenue
-242.03MNet Income

Analyst Ratings

42.00Average Price Target
The highest estimate is 44.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SRZNW. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is a biotech company that develops treatments for serious medical conditions, competing with Surrozen in the biopharmaceutical space, particularly in areas like regenerative medicine and tissue repair.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on creating new possibilities in medicine, including regenerative treatment options, which puts them in direct competition with Surrozen's efforts in tissue regeneration and repair.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing with Surrozen in the broader biopharmaceutical market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is at the forefront of RNAi therapeutics, competing with Surrozen in the innovative treatment market, including potential overlaps in target diseases or conditions.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is focused on developing gene-based medicines, which could compete with Surrozen's approach to using Wnt signaling for tissue repair and regeneration.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that operates in various therapeutic areas, including those that could overlap with Surrozen's focus on regenerative medicine and tissue repair.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global biopharmaceutical company with a broad range of therapeutic products, some of which may compete with Surrozen's treatments in regenerative medicine and tissue repair.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a research-based biopharmaceutical company that develops innovative medicines, potentially competing with Surrozen in areas like liver disease treatment, where regenerative medicine is key.

About

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Show more...
CEO
Craig Parker
Employees
44
Country
United States
ISIN
US86889P1176

Listings

0 Comments

Share your thoughts

FAQ

What is Surrozen stock price today?
The current price of SRZNW is $0.00 USD — it has decreased by -65.79% in the past 24 hours. Watch Surrozen stock price performance more closely on the chart.
What is Surrozen stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Surrozen stocks are traded under the ticker SRZNW.
What is Surrozen market cap?
Today Surrozen has the market capitalization of 15,279.63
When is the next Surrozen earnings date?
Surrozen is going to release the next earnings report on November 11, 2026.
What were Surrozen earnings last quarter?
SRZNW earnings for the last quarter are -0.41 USD per share, whereas the estimation was -1.29 USD resulting in a +68.17% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Surrozen revenue for the last year?
Surrozen revenue for the last year amounts to 3.48M USD.
What is Surrozen net income for the last year?
SRZNW net income for the last year is -242.03M USD.
How many employees does Surrozen have?
As of September 04, 2026, the company has 44 employees.
In which sector is Surrozen located?
Surrozen operates in the Health & Wellness sector.
When did Surrozen complete a stock split?
The last stock split for Surrozen was on December 14, 2023 with a ratio of 1:15.
Where is Surrozen headquartered?
Surrozen is headquartered in SOUTH SAN FRANCISCO, United States.